Literature DB >> 25556681

Tumour-to-tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation-specific antibodies.

Yuki Katsuya1,2, Akihiko Yoshida1, Shun-Ichi Watanabe3, Koji Tsuta1.   

Abstract

AIMS: Tumour-to-tumour metastasis is a rare event. The aim of this study is to demonstrate the utility of mutation-specific antibodies to prove the occurrence of metastatic papillary thyroid cancer donor into lung adenocarcinoma recipient. METHODS AND
RESULTS: We report the case of an 80-year-old woman who had a papillary thyroid carcinoma with a v-raf murine sarcoma viral oncogene homologue B1 mutation that metastasized into a lung adenocarcinoma with an epidermal growth factor receptor mutation. Immunohistochemical analysis with mutation-specific antibodies not only clearly revealed two components, but also revealed their gene mutation statuses.
CONCLUSIONS: As a component of multimodal diagnostic tools, immunohistochemistry can avoid some pitfalls involved in the molecular diagnosis of complicated cases (such as our own) and can help to ensure that patients receive optimal treatments.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  gene mutation; immunohistochemistry; lung adenocarcinoma; papillary thyroid tumour; tumour-to-tumour metastasis

Mesh:

Substances:

Year:  2015        PMID: 25556681     DOI: 10.1111/his.12643

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Metastases to the Thyroid Gland: What Can We Do?

Authors:  Qiushi Tang; Zhihong Wang
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

2.  Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis.

Authors:  Andres M Acosta; Michael R Pins
Journal:  Virchows Arch       Date:  2015-10-31       Impact factor: 4.064

Review 3.  Metastasis to the Thyroid Gland: A Critical Review.

Authors:  Iain J Nixon; Andrés Coca-Pelaz; Anna I Kaleva; Asterios Triantafyllou; Peter Angelos; Randall P Owen; Alessandra Rinaldo; Ashok R Shaha; Carl E Silver; Alfio Ferlito
Journal:  Ann Surg Oncol       Date:  2016-11-21       Impact factor: 5.344

4.  TFF3 Contributes to Epithelial-Mesenchymal Transition (EMT) in Papillary Thyroid Carcinoma Cells via the MAPK/ERK Signaling Pathway.

Authors:  Xu Lin; Huiqin Zhang; Jin Dai; Wenjing Zhang; Jing Zhang; Gang Xue; Jingfang Wu
Journal:  J Cancer       Date:  2018-10-31       Impact factor: 4.207

5.  Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example.

Authors:  Lorenzo Gerratana; Giovanna De Maglio; Alessandro De Pellegrin; Alessandro Follador; Karim Rihawi; Stefano Pizzolitto; Fabio Puglisi; Gianpiero Fasola
Journal:  Onco Targets Ther       Date:  2016-08-30       Impact factor: 4.147

6.  Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma.

Authors:  Bin Zhou; Hailin Shan; Ying Su; Kai Xia; Runlong Zou; Qing Shao
Journal:  Oncotarget       Date:  2017-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.